Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Iksuda Therapeutics

News headline image
Iksuda to Present First Clinical Data for IKS03 in Advanced B-Cell Non-Hodgkin Lymphomas at ASH
From Iksuda Therapeutics
Via Business Wire
News headline image
Iksuda to Present Clinical Data for IKS014 in HER2+ Solid Tumours at SABCS
From Iksuda Therapeutics
Via Business Wire
News headline image
Iksuda receives US FDA IND clearance for IKS04
From Iksuda Therapeutics
Via Business Wire
News headline image
Iksuda to Present Preliminary Analysis of Oesophageal Cancer Data From Phase 1 study of IKS014 at ASCO Gastrointestinal Cancer Symposium
From Iksuda Therapeutics
Via Business Wire
News headline image
Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO
From Iksuda Therapeutics
Via Business Wire
News headline image
Iksuda to Present IKS014 Phase 1 Data at ESMO
From Iksuda Therapeutics
Via Business Wire
News headline image
Iksuda Therapeutics Receives FDA IND Clearance for IKS014
From Iksuda Therapeutics
Via Business Wire
News headline image
Iksuda Therapeutics announces first patient successfully dosed in phase 1 trial evaluating IKS03 in advanced B cell non-Hodgkin lymphomas
From Iksuda Therapeutics
Via Business Wire
News headline image
Iksuda to Present Growing ADC Pipeline at AACR
From Iksuda Therapeutics
Via Business Wire
News headline image
Iksuda Therapeutics announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2
From Iksuda Therapeutics
Via Business Wire
News headline image
Iksuda Therapeutics Deepens Clinical Pipeline Through Licensing Agreement for Her2 Antibody Drug Conjugate Programme From LegoChem Biosciences
From Iksuda Therapeutics
Via Business Wire
News headline image
LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates
From Iksuda Therapeutics
Via Business Wire
News headline image
Iksuda Therapeutics Closes $47 Million Financing Round
From Iksuda Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.